TECHNICAL DATA SHEET

PE Anti-Mouse Fc epsilon Receptor I alpha (FceR1) (MAR-1)

Catalog Number: 50-5898

PRODUCT INFORMATION

Contents: PE Anti-Mouse Fc epsilon Receptor I alpha (FceR1) (MAR-1)

Isotype: Armenian Hamster IgG

Concentration: 0.2 mg/mL

Clone: MAR-1

Reactivity: Mouse

Formulation: 10 mM NaH_2PO_4, 150 mM NaCl, 0.09% NaN_3, 0.1% gelatin, pH7.2



MC/9 (mouse mast cell line) cells were stained with 0.06 ug PE Anti-Mouse Fc epsilon Receptor I alpha (50-5898) (solid line) or 0.06 ug PE Armenian Hamster IgG isotype control (dashed line).

DESCRIPTION

The MAR-1 antibody reacts with the Fc epsilon Receptor I alpha chain (FceRIa), a transmembrane protein member of the Ig superfamily. This chain, together with a beta chain and two gamma chains form a tetrameric complex that supports IgE-mediated signaling and subsequent release of chemical mediators of allergy and immediate hypersensitivity. FceR1a is upregulated in the presence of IgE on those cell types which express it, such as Mast cells and Basophils. The MAR-1 antibody is widely used both in flow cytometry and for depletion of cells in vitro / in vivo.

PREPARATION & STORAGE

This monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation. It is recommended to store the product undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze.

APPLICATION NOTES

This antibody preparation has been quality-tested for flow cytometry using mouse spleen cells, or an appropriate cell type (where indicated). The amount of antibody required for optimal staining of a cell sample should be determined empirically in your system.

REFERENCES

Mukai K, BenBarak MJ, Tachibana M, Nishida K, Karasuyama H, Taniuchi I, and Galli SJ. 2012. Blood. 120: 76-85. (Flow cytometry) Smith KA, Harcus Y, Garbi N, Hammerling GJ, MacDonald AS, and Maizels RM. 2012. Infect. Immun. 80: 3481-3489. (in vivo depletion) Larson D, Hubner MP, Torrero MN, Morris CP, Brankin A, Swierczewski BE, Davies SJ, Vonakis BM, and Mitre E. 2012. J. Immunol. 188: 4188-4199. (in vitro activation) Khodoun M, Krishnamurthy D, Strait R, Kucuk Y, and Finkelman F. 2011. J. Immunol. 186: 151.4. (in vitro depletion)

NOTE: Please choose the appropriate format for each application. Citations are provided as a convenience to you; please consult Materials and Methods sections for additional details about the use of any product in these publications.